CClinicalTrials.gg
Not yet recruitingNCT06063304Updated Oct 2, 2023

Quantitative MRI For Detection and Tracking of Knee Osteoarthritis

An observational study in Knee Osteoarthritis, sponsored by Imperial College London. Not yet recruiting. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-02.

Sponsored by Imperial College London · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
70
Ages
40 Years to 70 Years
Sex
All
01

Study summary

The goal of this observational study is to develop whole-joint quantitative MRI techniques that aid in the detection and tracking of osteoarthritis disease progression at 3T and 7T MRI scanners. The research objectives are:

  1. Compare the relative accuracies of 7T and 3T MRI in detecting clinical osteoarthritis progression.
  2. Compare the quantitative MRI measures developed with the results acquired from the following two questionnaires: Knee Injury and Osteoarthritis Outcome Score (KOOS) and the Visual Analogue Score (VAS).
  3. Measure the repeatability of 7T and 3T quantitative MRI methods developed in whole-joint knee imaging
  4. Optimize the quality and efficiency of 7T and 3T whole-joint knee MRI

Participants will be scanned at the 3T scanner at the Clinical Imaging Facility at Hammersmith Hospital and/or the 7T scanner at the LOCUS Center at St Thomas' Hospital. Knee osteoarthritis volunteers will be asked to fill out two questionnaires and will be scanned 4 times over a 2 year period (at enrolment, after 6 months, after 12 months and after 24 months) while healthy volunteers will be scanned once at enrolment. Both healthy volunteers and knee osteoarthritis patients will be asked to fill out MRI safety forms before entering the scanner room, and both groups will be scanned up to 90 minutes during each session.

Researchers will compare knee osteoarthritis patients with healthy volunteers to see how their knee anatomy and tissue properties differ.

02

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Knee Osteoarthritis
  • Healthy Volunteer
  • MRI
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's planned enrollment of 70 is below the median of 100 across 791 observational studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Imperial College London is the lead sponsor of 824 studies on the registry; 178 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The research team will be recruiting both healthy volunteers and early knee osteoarthritis patients using the inclusion and exclusion criteria detailed above.

Inclusion criteria

  • All people between 40 to 70 years of age
  • All people with no history of knee injury, surgery, or knee pain

Exclusion criteria

Exclusion Criteria For Healthy Volunteers:

  • Patients with body mass index of more than 35, or body geometry that prevents scanning due to MRI scanner bore width or knee coil diameter
  • Patients with varus or valgus malalignment
  • Patients with contraindications to MRI
  • Patients lacking capacity to consent
  • Patients who are pregnant or breast-feeding
  • Patients who are participating in a clinical trial(s) for new drugs and/or therapies

Inclusion Criteria for Knee Osteoarthritis Patients:

  • All patients with primary osteoarthritis (grade 2-3 per Kellgren-Lawrence Scale)
  • Patients who have had radiographs taken as part of their routine clinical care agreed with their orthopaedic surgeon, Mr Gareth Jones. Note that their radiographs must have been acquired a maximum of three weeks from the first, baseline scanning session. This radiograph will be used to check if patients have primary osteoarthritis.
  • All patients between 40 to 70 years of age

Exclusion Criteria for Knee Osteoarthritis Patients

  • Patients with body mass index of more than 35, or body geometry that prevents scanning due to MRI scanner bore width or knee coil diameter
  • Patients with varus or valgus malalignment of more than 5°
  • Patients with radiographic osteoarthritis (grade ≥4 per Kellgren-Lawrence Scale, obtained from radiographs)
  • Patients with contraindications to MRI
  • Patients lacking capacity to consent
  • Patients who are pregnant or breast-feeding
  • Patients who are participating in a clinical trial(s) for new drugs and/or therapies
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy Volunteers

    This group consists of healthy volunteers with no history of knee joint pain (refer to inclusion/exclusion criteria for more details). They will be scanned once and their scans will be used as the baseline to compare the early knee osteoarthritis patient data with. 10 healthy volunteers will be recruited.

  • Knee Osteoarthritis Patients

    This group consists of early knee osteoarthritis patients (refer to inclusion/exclusion criteria for more details). They will be scanned 4 times over a period of 2 years (at enrolment, 6 months, 12 months and 24 months after enrolment) to see how the disease progresses. Their scans will be compared with the baseline healthy volunteer scans to check for any differences in anatomy and tissue properties. 60 knee osteoarthritis patients will be recruited.

06

What researchers measure

Primary outcomes

  1. Reproducibility of cartilage thickness values at 3T and 7T as a measure of knee osteoarthritis at enrolment, after 6 months, after 12 months and after 24 months

    The cartilage thickness values will be calculated from the MRI scans that will be acquired.

    Time frame: at enrolment, after 6 months, after 12 months and after 24 months

Secondary outcomes

  1. Reproducibility of microstructure maps at 3T and 7T as a measure of knee osteoarthritis at enrolment, after 6 months, after 12 months and after 24 months

    The microstructure maps will be calculated from the MRI scans that will be acquired.

    Time frame: at enrolment, after 6 months, after 12 months and after 24 months

  2. Reproducibility of MOAKS analysis at 3T and 7T as a measure of knee osteoarthritis at enrolment, after 6 months, after 12 months and after 24 months

    MRI Osteoarthritis Knee Score (MOAKS) values will be calculated from the MRI scans that will be acquired. MOAKS is a semi-quantitative scoring tool that scores sub-regions of articular cartilage and bone marrow lesions. Different grades are used to score each sub-region. For cartilage sub-region loss, grade 0 indicates no loss and grade 3 indicates over 75% loss.

    Time frame: at enrolment, after 6 months, after 12 months and after 24 months

  3. Calculate and compare the longitudinal changes in cartilage thickness at 3T and 7T over the 2 year period

    Cartilage thickness will be calculated for scans acquired at the various time points on the 3T and 7T scanners and compared with each other to investigate the change in thickness over the specified time frame.

    Time frame: at enrolment, after 6 months, after 12 months and after 24 months

  4. Calculate and compare the longitudinal changes in microstructure maps at 3T and 7T over the 2 year period

    Microstructure maps will be calculated for scans acquired at the various time points on the 3T and 7T scanners and compared with each other to investigate the change in thickness over the specified time frame.

    Time frame: at enrolment, after 6 months, after 12 months and after 24 months

  5. Calculate minimum detectable effect size for osteoarthritis progression at 3T and 7T with cartilage thickness

    Time frame: at enrolment, after 6 months, after 12 months and after 24 months

  6. Calculate minimum detectable effect size for osteoarthritis progression at 3T and 7T with microstructure maps

    Time frame: at enrolment, after 6 months, after 12 months and after 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — We will not be sharing IPD with other researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06063304
Lead sponsor
Imperial College London
Collaborators
Imperial College Healthcare NHS Trust
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Oct 2023 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Oct 2, 2023

Study contacts

Neal K Bangerter, PhD
Contact
n.bangerter@imperial.ac.uk
7534066791 ext. +44
Peter J Lally, PhD
Contact
p.lally@imperial.ac.uk
7976905576 ext. +44
Neal K Bangerter, PhD
principal investigator · Imperial College London

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion